Form 4: Drugs Made In America Acquisition Corp. Director Lynn Stockwell Reports Share Transfers

Lynn Stockwell, a director, 10% owner, CEO, and Executive COB of Drugs Made In America Acquisition Corp., reported the transfer and disposal of ordinary shares and rights to receive ordinary shares on January 29, 2025.

Summary

• On January 29, 2025, Lynn Stockwell, a director, 10% owner, CEO, and Executive COB of Drugs Made In America Acquisition Corp. (DMAA), filed a Form 4.
• The report details several transactions involving ordinary shares and rights to receive ordinary shares.
• Stockwell indirectly acquired 400,000 ordinary shares through Drugs Made In America Acquisition LLC, the Issuer's sponsor.
• The sponsor transferred 400,000 ordinary shares to certain of the Issuer's officers and directors for no consideration.
• The sponsor also transferred 5,698,363 ordinary shares for consideration ranging from no consideration to $1.50 per share.
• Stockwell disclaims beneficial ownership of the securities held by the sponsor, except to the extent of her pecuniary interest therein.
• The rights to receive ordinary shares convert automatically upon the completion of the Issuer's initial business combination.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document primarily reports transactions and ownership details, without expressing a clear positive or negative outlook. The transfers of shares could be seen as a positive sign of aligning incentives, but also potentially dilutive to existing shareholders.

Future Outlook

The rights to receive ordinary shares will convert automatically into ordinary shares at the completion of the Issuer's initial business combination.

Management Comments

• Ms. Stockwell disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of her pecuniary interest therein.

Industry Context

This filing is typical for SPACs (Special Purpose Acquisition Companies) like Drugs Made In America Acquisition Corp., where insiders and sponsors often receive shares and warrants as part of the initial capitalization and deal structuring. The transfers to officers and directors are also common to align incentives.

Comparison to Industry Standards

• The structure of private units consisting of ordinary shares and rights to receive additional shares is a common feature in SPAC offerings, similar to units offered by companies like Churchill Capital Corp.
• The transfer of shares to officers and directors for nominal or no consideration is also a standard practice, comparable to arrangements seen in other SPACs such as Pershing Square Tontine Holdings.
• The pricing of share transfers at $1.50 per share is within the range observed in similar transactions involving SPAC sponsors and insiders, although some transfers may occur at no cost.

Related Party Transactions

• The transactions involving the sponsor, Drugs Made In America Acquisition LLC, and its relationship with Lynn Stockwell constitute related party transactions.

Stakeholder Impact

• The transfer of shares to officers and directors could impact shareholder value depending on the future performance of the company.
• The conversion of rights to ordinary shares upon business combination will dilute existing shareholders.

Next Steps

• The rights to receive ordinary shares will convert automatically upon the completion of the Issuer's initial business combination.

Key Dates

Keywords

Form 4, beneficial ownership, ordinary shares, Drugs Made In America Acquisition Corp., Stockwell, sponsor, DMAA, rights